Dr. Wenwen Bi obtained her Ph.D. of Pathogen Biology from School of Basic Medical Sciences at Fudan University in 2020. During her doctoral training, she received joint training in Dr. Lishan Su’s lab in the Lineberger Comprehensive Cancer Center at University of North Carolina at Chapel Hill. From 2020 to 2022, she received her postdoctoral training in the Institute of Life Sciences at Westlake University. In 2022, she joined Hangzhou Global Scientific and Technological Innovation Center at Zhejiang University as an associate professor and young investigator.

Her major research interest is the mechanism of viruses (including HIV, SARS-CoV-2 and influenza) infection target cells, and prevention and treatment strategies against viruses by antiviral agents and vaccines.

In the past five years, she has published 4 papers in the high-impact journals (Cell Research, Cell Reports Medicine, Plos Pathogens, Journal of Virology) as the first or corresponding author and obtained 2 granted patents in China. She has received 2 grants from the National Natural Science Foundation of China and the China Postdoctoral Program as the project leader.

• Biotechnology

• Wenwen Bi*(Co-corresponding Author), Kaiming Tang, Guilin Chen, Yubin Xie, Nicholas F Polizzi, William F DeGrado, Shuofeng Yuan*, Bobo Dang*. An enhanced broad-spectrum peptide inhibits Omicron variants in vivo. Cell Rep Med. 2024 Feb 20;5(2):101418.
• Wenwen Bi*(Co-corresponding Author), Guilin Chen, Bobo Dang*. Novel Engineered SARS-CoV-2 HR1 Trimer Exhibits Improved Potency and Broad-spectrum Activity against SARS-CoV-2 and Its Variants. J Virol. 2022 Jul 13;96(13):e0068122.
• Ying Tao#, Sumin Bian#, Pengbo Wang, Hongyong Zhang, Wenwen Bi, Peixi Zhu*, Mohamad Sawan. Rapid Optical Biosensing of SARS-CoV-2 Spike Proteins in Artificial Samples. Sensors (Basel). 2022 May 16; 22(10): 3768.
• engjiao Li#, Zi-Wei Ye#, Kaiming Tang#, Liang Guo#, Wenwen Bi, Yuyuan Zhang, Yan-Dong Tang, Guoguang Rong, Mohamad Sawan, Xin Yin, Ren Sun, Shuofeng Yuan*, Bobo Dang*. Enhanced trimeric ACE2 exhibits potent prophylactic and therapeutic efficacy against the SARS-CoV-2 Delta and Omicron variants in vivo. Cell Res. 2022 Apr 13;1-4. doi: 10.1038/s41422-022-00656-4.
• Liang Guo#, Wenwen Bi #(Co-first Author), Xinling Wang#, Wei Xu#, Renhong Yan#, Yuanyuan Zhang#, Kai Zhao, Yaning Li, Mingfeng Zhang, Xia Cai, Shibo Jiang, Youhua Xie, Qiang Zhou*, Lu Lu*, Bobo Dang*. Engineered trimeric ACE2 binds viral spike protein and locks it in "Three-up" conformation to potently inhibit SARS-CoV-2 infection. Cell Res. 2021 Jan;31(1):98-100.
• Qian Wang#, Shan Su#, Jing Xue#, Fei Yu, Jing Pu, Wenwen Bi, Shuai Xia, Yu Meng, Cong Wang, Wenqian Yang, Wei Xu, Yun Zhu, Qinwen Zheng, Chuan Qin*, Shibo Jiang*, Lu Lu*. An amphipathic peptide targeting the gp41 cytoplasmic tail kills HIV-1 virions and infected cells. Sci Transl Med. 2020 Jun 3;12(546):eaaz2254.
• Bi Wenwen#, Xu Wei#, Cheng Liang, Xue Jing, Wang Qian, Yu Fei, Xia Shuai, Wang Qi, Li Guangming, Qin Chuan, Lu Lu*, Su Lishan*, Jiang Shibo*. 2019. IgG Fc-binding motif-conjugated HIV-1 fusion inhibitor exhibits improved potency and in vivo half-life: Potential application in combination with broad neutralizing antibodies. PLoS Pathog. 2019 Dec 5;15(12):e1008082.
• Wang Qian#, Bi Wenwen# (Co-first Author), Zhu Xiaojie, Li Haoyang, Qi Qianqian, Yu Fei, Lu Lu*, Jiang Shibo*. 2015. Non-neutralizing antibodies induced by HIV-1 gp41 NHR domain gain neutralizing activity in the presence of HIV fusion inhibitor enfuvirtide: a potential therapeutic vaccine strategy. J Virol. 2015 Jul;89(13):6960-4.

No content available to display!!!

No content available to display!!!